EUVIMEDEUVIMED entdecken
Open Access

Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model

Shan Huang, Ling Ren, Jessica A Beck, Tim E Phelps iD, Colleen Olkowski, Anita Ton, Jyoti Roy iD, Margaret E White, Stephen Adler, Karen Wong, Aswini Cherukuri, Xiang Zhang und 4 weitere

Cancer Biotherapy and Radiopharmaceuticals · 2023

DOI: 10.1089/cbr.2022.0090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, 2023. Verfasst von Shan Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Metformin, Bone Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osteosarcoma (OS) is an aggressive pediatric cancer with unmet therapeutic needs. Glutaminase 1 (GLS1) inhibition, alone and in combination with metformin, disrupts the bioenergetic demands of tumor progression and metastasis, showing promise for clinical translation. Materials and Methods: Three positron emission tomography (PET) clinical imaging agents, [ 18 F]fluoro-2-deoxy-2-D-glucose ([ 18 F]FDG), 3′-[ 18 F]fluoro-3′-deoxythymidine ([ 18 F]FLT), and (2S, 4R)-4-[ 18 F]fluoroglutamine ([ 18 F]GLN), were evaluated in the MG63.3 human OS xenograft mouse model, as companion imaging biomarkers after treatment for 7 d with a selective GLS1 inhibitor (CB-839, telaglenastat) and metformin, alone and in combination. Imaging and biodistribution data were collected from tumors and reference tissues before and after treatment.

Results

Drug treatment altered tumor uptake of all three PET agents. Relative [ 18 F]FDG uptake decreased significantly after telaglenastat treatment, but not within control and metformin-only groups. [ 18 F]FLT tumor uptake appears to be negatively affected by tumor size. Evidence of a flare effect was seen with [ 18 F]FLT imaging after treatment. Telaglenastat had a broad influence on [ 18 F]GLN uptake in tumor and normal tissues.

Conclusions

Image-based tumor volume quantification is recommended for this paratibial tumor model. The performance of [ 18 F]FLT and [ 18 F]GLN was affected by tumor size. [ 18 F]FDG may be useful in detecting telaglenastat's impact on glycolysis. Exploration of kinetic tracer uptake protocols is needed to define clinically relevant patterns of [ 18 F]GLN uptake in patients receiving telaglenastat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaMetforminBone NeoplasmsHumansMiceAnimalsChildFluorodeoxyglucose F18Tissue DistributionHeterograftsPositron-Emission TomographyDisease Models, AnimalBiomarkersRadiopharmaceuticals

Stichwörter der Autor:innen

[18F]FDG[18F]FLT[18F]GLNmetforminosteosarcomatelaglenastat

Substanzen

Fluorodeoxyglucose F18MetforminBiomarkersRadiopharmaceuticals

Autor:innen und Institutionen

  • Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Laboratory of Genitourinary Cancer Pathogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland, USA.
  • Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Tim E Phelps, Jyoti Roy, Elaine M Jagoda, Amy K LeBlanc

Zitieren

APA

Huang, S., Ren, L., Beck, J. A., Phelps, T. E., Olkowski, C., Ton, A., Roy, J., White, M. E., Adler, S., Wong, K., Cherukuri, A., Zhang, X., Basuli, F., Choyke, P. L., Jagoda, E. M., & LeBlanc, A. K. (2023). Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2022.0090

Vancouver

Huang S, Ren L, Beck JA, Phelps TE, Olkowski C, Ton A, et al. Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model. Cancer Biotherapy and Radiopharmaceuticals. 2023. doi:10.1089/cbr.2022.0090

BibTeX
@article{Huang2023,
  author = {Huang, Shan and Ren, Ling and Beck, Jessica A and Phelps, Tim E and Olkowski, Colleen and Ton, Anita and Roy, Jyoti and White, Margaret E and Adler, Stephen and Wong, Karen and Cherukuri, Aswini and Zhang, Xiang and Basuli, Falguni and Choyke, Peter L and Jagoda, Elaine M and LeBlanc, Amy K},
  title = {Exploration of Imaging Biomarkers for Metabolically-Targeted Osteosarcoma Therapy in a Murine Xenograft Model},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2023},
  doi = {10.1089/cbr.2022.0090}
}
Kostenlos starten →